Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (4243)	12/8/2001 3:50:33 PM
From: edlinedkar	Read Replies (1) \| Respond to of 5665

Gary, I am not sure if Mitch was asked about the 60% tumor reduction, in the break out session after his presentation at the Stock Holders Meeting. What I can add to what you have said is this. The information about the 60% was never volunteered. The answer came about because in the Break out session, Dr. Lambert was asked to talk about those results, and asked why the patient relapsed. He said that the patient relapsed because they had to stop treating the patient because of severe Diarhea brought on by his/her condition, and had nothing to do with the treatment/dosing. It took awhile to address this problem, and since no treatments were being given, there was a relapse. What we know about this patient, only came about because Dr. Lambert was asked, and he was kind enough to answer. I am not sure that we would have ever found out if we did not have that Stock Holders Meeting and break out session. Is there is anyone out there that can say that they talked to someone from the company that has given a similar answer to that question, they have not been mentioned, to my knowledge. Ed